After three years of comment review, the FDA has issued a final guidance on patient-reported outcome (PRO) instruments submitted in applications. Sponsors should define the role a PRO endpoint plays in trials so appropriate statistical methods can be planned and applied, the guidance says. The guidance revises a February 2006 draft, for which the agency received 22 comments.
Clinical Trials Advisor